Table 3.
Trials | Initiation year | Country/Region | Cell source/Dose | Administration route | Population | Outcome | Status | Reference | |
---|---|---|---|---|---|---|---|---|---|
Safety | NT2/D1 | Intracerebral | Basal ganglia stroke | Feasible | Completed | (Kondziolka et al., 2000),(Nelson et al., 2002) | |||
2001 | USA | NT2/D1 | Intracerebral | Stroke patients | Feasible with small risk of seizure | Completed | (Kondziolka et al., 2005) | ||
MSC | Intravenous | MCA | (Bang et al., 2005a) | ||||||
2005 | USA | ES | Intracerebral | Ischemic stroke patients | 2/5 patients showed improvements | Terminated | (Savitz et al., 2005) | ||
2008 | India | BMMNC | Intrathecal | Stroke patients | Completed | NCT02065778 | |||
2009 | Cuba | BMSC | Intracerebral | Stroke patients | Good tolerance and safety | Completed | (Suarez-Monteagudo et al., 2009) | ||
2010 | Brazil | BMMNC | Intra-arterial | Nonacute ischemic stroke | Feasible and safe | Completed | (Battistella et al., 2011) | ||
2011 | Japan | MSC | Intravenous | Stroke patients | Feasible and safe | Completed | (Honmou et al., 2011) | ||
2012 | Hong Kong | UCBMC | Intracranial | Stroke in the middle cerebral artery territory and stable hemiplegia or hemiparesis | N/A | Completed | NCT01673932 | ||
2012 | China | BMSC | Intracerebral | Ischemia stroke or ICH patient | No adverse effects observed; 87% functional/neurological improvement | Completed | (Li et al., 2013b) | ||
2012 | Brazil | BMMNC | Intra-arterial | MCA acute ischemic stroke | Safe | Completed | (Friedrich et al., 2012) | ||
2010 | France | MSC | Intravenous | Carotid ischemic stroke patients | Ongoing | NCT00875654 | |||
2010 | UK | NSC | Intracranial | Stroke patients | Ongoing | (Kalladka et al., 2016) | |||
2011 | Taiwan | OEC | Intracerebral | Thromboembolic Stroke | NCT01327768 | ||||
2012 | China | HSC | Intra-arterial | Internal carotid artery territory infarction | N/A | Recruiting | NCT01518231 | ||
2014 | Spain | BMMNC/2m/kg or 5m/kg | Intra-arterial | Moderate-to-severe acute ischemic stroke patients | Appears to be safe; 30% clinical improvement at 90 days | Recruiting | (Moniche et al., 2015) | ||
2014 | Mexico | NSC | Intravenous | Ischemic stroke | Ongoing | www.Novastem.mx | |||
2014 | China | NSC | Intracerebral | Chronic ischemia stroke | Completed | www.Neuralstem.com | |||
2014 | China | EPC | Intravenous | Chronic ischemia stroke | Recruiting | NCT01468064 | |||
2015 | China | UCMSC/20m | Intravenous | ICH | Ongoing | NCT02283879 | |||
2016 | China | UCMSC | Intravenous | Intracerebral ischemic stroke | - | NCT02580019 | |||
2016 | China | MSC | Intracerebral | ICH | Recruiting | NCT02767817 | |||
2016 | USA | BMSC | Intravenous/Intranasal | functional damage to CNS/PNS | Recruiting | NCT02795052 | |||
2016 | Taiwan | ADSC | Intracerebral | Stroke patients | - | NCT02813512 | |||
Efficacy | 2008 | Japan | BMMNC/25 ml | Intravenous | Stroke patients | Completed | (Toyoda, 2013) | ||
2009 | Taiwan | CD34+ Stem Cell | Intracerebral | Chronic stroke adult patient | Completed | (Mackie a,,nd Losordo, 2011); NCT01438593, NCT01249287 | |||
2011 | China | BMSC, EPC/2.5m/kg/100 ml | Intravenous | Ischemic lesion within the MCA territory | Ongoing | NCT01468064 | |||
2011 | USA | BMSC/2.5m 5.0m or 10m | Intracranial | Chronic stroke patients | No serious adverse events attributable and significant improvements in motor impairment | Completed | www.san-bio.com | ||
2014 | UK | NSC | Intracerebral | Stroke patient Phase II | Strongly positive results for 12 months; Well-tolerated/no serious adverse events | Ongoing | www.reneuron.com; NCT02117635 | ||
2014 | India | BMMNC | Intravenous | Ischemic stroke Phase II | Safe but no beneficial effect | Recruiting | (Prasad et al., 2014); NCT02245698 | ||
2016 | US/UK | MultiStem cells | Intravenous | Ischemic stroke Phase II | Excellent; 12-month functional improvement | Completed | www.athersys.com | ||
2016 | Europe | ADSC/1m/kg | Intravenous | Hemispheric ischemic stroke | Recruiting | NCT02849613 | |||
Effectiveness | 2013 | China | MSC | Intrathecal | Cerebral palsy | Recruiting | NCT01929434 |
This Table may not include all current clinical trials. The reference list includes published papers, searchable websites or ClinicalTrials.gov Identifiers. Abbreviation in the Table: ASC, Adipose-derived Stromal Cells; BMSC, bone marrow mesenchymal stem cell; EPC, endothelial progenitor cells; ES, embryonic stem cells; ICH, intracerebral hemorrhage; iPS, induced pluripotent stem cells; m indicates million cells; MCAO, middle cerebral artery occlusion; NSC, neural stem cells; UCBMC, umbilical cord blood mononuclear cells; UCMSC, umbilical cord mesenchymal stem cells.